Patent ID: 7951821

Claim:
A method of treating a disease selected from the group consisting of dementia, psychoses schizophrenia, acute or chronic extrapyramidal symptoms induced by neuroleptics, anxiety, panic attack, phobia, obsessive-compulsive disorder, depression, disorder due to alcohol abuse or withdrawal from alcohol, migraine, painful muscular contractures in rheumatology or acute spinal pathology, rebellious algia, Parkinson's disease, epilepsy, and sleep apnea in a patient comprising administering to said patient a therapeutically effective amount of a compound, in the form of a pure optical isomer (1S,2S) or in the form of a threo diastereoisomer, optionally in combination with a pharmaceutical excipient, wherein said compound is corresponding to general formula (1): wherein R 1 is either a hydrogen atom, or a linear or branched (C 1 -C 7 )alkyl group optionally substituted with one or more fluorine atoms, or a (C 3 -C 7 )cycloalkyl(C 1 -C 3 )alkyl group, or a phenyl(C 1 -C 3 )alkyl group optionally substituted with one or two methoxy groups, or a (C 2 -C 4 )alkenyl group, or a (C 2 -C 4 )alkynyl group, X is a hydrogen atom or one or more substituents chosen from halogen atoms and trifluoromnethyl, linear or branched (C 1 -C 4 )alkyl and (C 1 -C 4 )alkoxy groups, R 2 is one or more substituents chosen from halogen atoms; and said compound in the form of a free base or of an addition salt with an acid.